Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Proof-of-concept Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer.
Brief Summary: SHIVA is a proof of concept randomized phase II trial which compares two treatment strategies for patients with refractory cancer.

From a tumor biopsy, a molecular profile of the disease is established (mutations, amplifications, hormone receptor status). If a molecular abnormality is identified for which an approved targeted agent is available, patients are randomized randomized between two arms:

* Targeted therapy based on the molecular profile
* Conventional therapy based on investigator's choice.

A cross-over is proposed at disease progression.


Options:
A: Arm Label: Ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab, Drug: Oxaliplatin, Drug: Leucovorin, Drug: 5-Fluorouracil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Oxaliplatin, Drug: Leucovorin, Drug: 5-Fluorouracil | Intervention Type: BIOLOGICAL; Name: Ramucirumab; Assigned to Arm(s): Ramucirumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Placebo, Ramucirumab | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Placebo, Ramucirumab | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Placebo, Ramucirumab
B: Arm Label: Standard chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tumor biopsy, Drug: Standard Chemotherapy | Arm Label: Personalized treatment; Type: EXPERIMENTAL; Interventions: Drug: Targeted therapy based on molecular profiling : Imatinib, Procedure: Tumor biopsy, Drug: Targeted therapy based on molecular profiling : Everolimus, Drug: Targeted therapy based on molecular profiling : Vemurafenib, Drug: Targeted therapy based on molecular profiling : Sorafenib, Drug: Targeted therapy based on molecular profiling : Erlotinib, Drug: Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab, Drug: Targeted therapy based on molecular profiling : Dasatinib, Drug: Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication), Drug: Targeted therapy based on molecular profiling : Abiraterone | Intervention Type: DRUG; Name: Targeted therapy based on molecular profiling : Imatinib; Assigned to Arm(s): Personalized treatment | Intervention Type: PROCEDURE; Name: Tumor biopsy; Assigned to Arm(s): Personalized treatment, Standard chemotherapy | Intervention Type: DRUG; Name: Standard Chemotherapy; Assigned to Arm(s): Standard chemotherapy | Intervention Type: DRUG; Name: Targeted therapy based on molecular profiling : Everolimus; Assigned to Arm(s): Personalized treatment | Intervention Type: DRUG; Name: Targeted therapy based on molecular profiling : Vemurafenib; Assigned to Arm(s): Personalized treatment | Intervention Type: DRUG; Name: Targeted therapy based on molecular profiling : Sorafenib; Assigned to Arm(s): Personalized treatment | Intervention Type: DRUG; Name: Targeted therapy based on molecular profiling : Erlotinib; Assigned to Arm(s): Personalized treatment | Intervention Type: DRUG; Name: Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab; Assigned to Arm(s): Personalized treatment | Intervention Type: DRUG; Name: Targeted therapy based on molecular profiling : Dasatinib; Assigned to Arm(s): Personalized treatment | Intervention Type: DRUG; Name: Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication); Assigned to Arm(s): Personalized treatment | Intervention Type: DRUG; Name: Targeted therapy based on molecular profiling : Abiraterone; Assigned to Arm(s): Personalized treatment
C: Arm Label: MLN0128P 30 mg QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 40 mg QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 6 mg QD×3d QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 7 mg QD×3d QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 8 mg QD×3d QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 9 mg QD×3d QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 10 mg QD×3d QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 7 mg QD×5d QW; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128P 8 mg QD×3d QW HER2-; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel | Arm Label: MLN0128PH 8 mg QD×3d QW HER2+; Type: EXPERIMENTAL; Interventions: Drug: MLN0128, Drug: paclitaxel, Drug: trastuzumab | Intervention Type: DRUG; Name: MLN0128; Assigned to Arm(s): MLN0128P 10 mg QD×3d QW, MLN0128P 30 mg QW, MLN0128P 40 mg QW, MLN0128P 6 mg QD×3d QW, MLN0128P 7 mg QD×3d QW, MLN0128P 7 mg QD×5d QW, MLN0128P 8 mg QD×3d QW, MLN0128P 8 mg QD×3d QW HER2-, MLN0128P 9 mg QD×3d QW, MLN0128PH 8 mg QD×3d QW HER2+ | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): MLN0128P 10 mg QD×3d QW, MLN0128P 30 mg QW, MLN0128P 40 mg QW, MLN0128P 6 mg QD×3d QW, MLN0128P 7 mg QD×3d QW, MLN0128P 7 mg QD×5d QW, MLN0128P 8 mg QD×3d QW, MLN0128P 8 mg QD×3d QW HER2-, MLN0128P 9 mg QD×3d QW, MLN0128PH 8 mg QD×3d QW HER2+ | Intervention Type: DRUG; Name: trastuzumab; Assigned to Arm(s): MLN0128PH 8 mg QD×3d QW HER2+
D: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Capecitabine, Drug: Cisplatin, Drug: 5-fluorouracil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Cisplatin, Drug: Placebo, Drug: 5-fluorouracil | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): Bevacizumab, Placebo

Answer: B